{"filings":[{"id":1591322,"accession_number":"0001213900-26-077296","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2026-07-10T22:29:27+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Silo Pharma raises $4M in private placement; warrants could add $7.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 619,965 shares (or pre-funded warrants) at $6.452/share plus Series A-3 and A-4 warrants.","Warrants exercisable at $6.21/share; Series A-3 expire 5 years, Series A-4 expire 18 months after registration.","Net proceeds expected ~$3.5M after fees; H.C. Wainwright acted as placement agent.","Proceeds to be used for working capital and general corporate purposes.","Potential additional $7.7M if all warrants exercised for cash; no assurance of exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1140757,"accession_number":"0001213900-26-070212","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2026-06-18T21:15:27+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq confirmation on June 17, 2026, that it regained compliance with Listing Rule 5550(a)(2).","Closing bid price was $1.00 or greater from June 3 to June 16, 2026, satisfying the requirement.","Nasdaq considers the matter closed; SILO continues trading on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":835756,"accession_number":"0001213900-26-064804","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2026-06-03T21:00:52+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Every 15 shares of common stock combined into 1 share; par value unchanged at $0.0001.","Authorized shares reduced proportionately from 100M to approximately 6.67M.","Fractional shares rounded up to the next whole share; no fractional shares issued.","Common stock trades under same symbol SILO but with new CUSIP 82711P 300.","Split-adjusted trading began on The Nasdaq Capital Market on June 3, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":760276,"accession_number":"0001213900-26-063185","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2026-06-01T13:02:13+00:00","items":["8.01"],"status":"ready","headline":"Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-15 reverse split effective 4:01 pm ET on June 2, 2026; post-split trading begins June 3 under same symbol SILO.","Outstanding shares reduced from ~16.267M to ~1.084M; authorized shares cut proportionately to 6,666,667.","CUSIP changes to 82711P 300; fractional shares rounded up to the next whole share.","Equitable adjustments made to equity awards and warrants, including exercise prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93313,"accession_number":"0001213900-26-039352","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Silo Pharma acquires QwikAgents software and domains for 2.1M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset purchase agreement with Many Ads Inc. for QwikAgents web application and domain names (qwikagents.com, .ai, .co).","Consideration: 2,100,000 unregistered shares of Silo Pharma common stock, issued under Section 4(a)(2) exemption.","Agreement includes customary representations, warranties, and indemnification provisions; liability capped at Purchase Price.","Software includes Next.js/React portal and MCP server; open-source components disclosed (LGPL dependency noted).","Transaction closed on March 30, 2026; domain transfer pending registrar processing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104837,"accession_number":"0001213900-26-019384","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Silo Pharma authorizes $1M buyback; pays IR consultant 848k shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved stock repurchase program up to $1 million of common stock.","Shares outstanding: 13,318,273 as of Sept 30, 2025.","Issued 848,320 shares to IR consultant as $250k commitment fee at $0.2947/share.","No proceeds received; shares issued under Section 4(a)(2) exemption.","Buyback discretionary; may be suspended or discontinued anytime."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121108,"accession_number":"0001213900-25-125838","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Silo Pharma receives Nasdaq extension until June 22, 2026 to regain minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company failed to meet $1.00 minimum bid price requirement by initial Dec. 24, 2025 deadline.","Nasdaq granted a 180-day extension, new compliance deadline is June 22, 2026.","Common stock continues trading on The Nasdaq Capital Market under symbol SILO.","If bid price closes at or above $1.00 for 10 consecutive business days, compliance will be achieved.","Company may consider a reverse stock split during second compliance period if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121107,"accession_number":"0001213900-25-102222","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.","Omnibus equity plan share reserve raised from 470,000 to 1,400,000 shares, plus automatic annual increase.","All four director nominees re-elected; ratification of Salberg & Company as auditor approved.","Reverse split proposal received 3,896,499 for vs 1,253,332 against; plan amendment got 1,343,678 for vs 514,675 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121106,"accession_number":"0001213900-25-094711","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Silo Pharma closes $2.5M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,857,143 shares at $0.875/share; gross proceeds ~$2.5 million.","Issued warrants to purchase 2,857,143 shares at $0.75, exercisable immediately, 5-year term.","H.C. Wainwright received 7.5% cash fee plus warrants for 214,285 shares at $1.0938.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137746,"accession_number":"0001213900-25-072062","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma launches crypto treasury strategy; appoints Corwin Yu to advisory board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board established Crypto Advisory Board (up to 3 members); appointed Corwin Yu as first member.","Yu granted options for 45,000 shares at $0.7757, vesting in 12 monthly installments.","Treasury strategy to buy Bitcoin, Ethereum, Solana; staking for yield; uses AI market intelligence.","Company reaffirms core biopharma focus; SPC-15 PTSD drug completing pre-IND studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137745,"accession_number":"0001213900-25-068740","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Silo Pharma acquires crypto software and domain assets for 750,000 shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired software for r2crypto.com and domain names socialscan.info, coinfeel.net, r2crypto.com from MAVS Holdings LLC.","Consideration: 750,000 shares of common stock (par value $0.0001) issued to Seller.","Also acquired six additional crypto-related domain names: silo-crypto.com, silocrypto.com, silocrypto.ai, siloholdingsinc.com, silocryptoholdings.com, silopharmaventures.com.","Agreement includes customary representations, warranties, and Seller indemnification for breaches and infringement.","Shares issued in reliance on Section 4(a)(2) private placement exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137744,"accession_number":"0001213900-25-062805","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Silo Pharma terminates UMB license, enters evaluation license and option for CNS-homing peptides","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminates 2021 Master License Agreement with University of Maryland, Baltimore effective June 30, 2025.","Gains exclusive evaluation license for CNS-homing peptides for non-clinical research through March 31, 2026.","Holds option to negotiate a commercial license for neuroinflammatory disease; exercise requires $1,000 fee and plan.","Derived IP created during evaluation automatically assigned to UMB; if option exercised, it enters new license.","U.S. Government retains rights under Federal IP Policy; agreement subject to existing third-party commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137743,"accession_number":"0001213900-25-061531","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Silo Pharma receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Silo of non-compliance with minimum bid price rule after 30 consecutive business days below $1.00, from May 14 to June 26, 2025.","Company has 180 calendar days, until December 24, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.","If not cured, an additional 180-day period may be granted; the Company may consider a reverse stock split to address the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155134,"accession_number":"0001213900-25-044913","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Silo Pharma closes $2M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 3,333,338 shares (or pre-funded warrants) plus Series A-1 and A-2 warrants for up to 3,333,338 shares each.","Combined price $0.60/unit; gross proceeds ~$2M, net ~$1.56M after fees and expenses.","Series A-1 warrants exercise price $0.60, expire 5 years; Series A-2 warrants $0.60, expire 18 months from issuance.","H.C. Wainwright exclusive placement agent; received 7.5% cash fee, 1% management fee, and 250,000 warrants at $0.75.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173654,"accession_number":"0001213900-25-021916","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Silo Pharma provides pipeline update; pre-IND for SPC-15 pending FDA guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lead asset SPC-15 (intranasal PTSD treatment) aims for first-in-human trials after FDA pre-IND feedback.","Exclusive global licenses from Columbia University for SPC-15 and SPC-14 (Alzheimer's).","SP-26 (ketamine implant for fibromyalgia) March 2025 data expected; 505(b)(2) pathway planned.","SPC-14 (Alzheimer's) and SPU-16 (multiple sclerosis) in preclinical with 2025 data targets.","Company states sufficient capital resources and no debt to support upcoming catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173653,"accession_number":"0001213900-25-021345","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma receives US patent for stress-induced affective disorder prophylactics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO granted Patent No. 12,239,614 for exclusively licensed Columbia University technology.","Patent titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females'.","Patent covers prophylactic treatment for stress-induced affective disorders specifically in females.","License is exclusive from Columbia University; patent application originally filed as 17/954864."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173652,"accession_number":"0001213900-25-000191","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.","SP-26 ketamine implant for fibromyalgia nearing first animal studies in early 2025; aims for at-home injectable therapeutic.","Both SPC-15 and SP-26 may qualify for FDA's streamlined 505(b)(2) approval pathway, reducing costs and time.","Cash on hand and minimal debt provide financial flexibility; no specific financial guidance disclosed.","Exclusive global license from Columbia University for SPC-15 pre-clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190614,"accession_number":"0001213900-24-111256","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Silo Pharma shareholders re-elect board, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees re-elected: Weisblum (578,427 for, 72,755 withhold), Linsley, Munoz, Pavell.","Ratification of Salberg & Company as auditor passed: 1,923,935 for, 32,111 against, 1,253 abstain.","Non-binding say-on-pay approved: 535,251 for, 104,162 against, 11,769 abstain (1,306,117 broker non-votes).","Frequency for future say-on-pay votes set at 3 years: 410,013 votes; 1 year got 196,384; 2 years 26,300.","Adjournment proposal approved: 1,778,053 for, 168,713 against, 10,533 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190613,"accession_number":"0001213900-24-095886","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Silo Pharma postpones 2024 annual meeting to Dec 20, 2024; new record date Nov 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting originally Nov 12, 2024, now rescheduled to Dec 20, 2024.","New record date set as Nov 12, 2024, for stockholders entitled to vote.","Stockholders must resubmit votes even if previously voted; new notice will be sent.","No other material changes disclosed; meeting business remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207105,"accession_number":"0001213900-24-077111","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Silo Pharma posts investor presentation for Sep 2024 conference; notes SPC-15 pre-IND submitted","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Presentation used at H.C. Wainwright 26th Annual Global Investment Conference on Sep 10, 2024.","Lead asset SPC-15 (intranasal PTSD treatment) pre-IND submitted for first-in-human trials.","Pipeline also includes SP-26 (ketamine implant for fibromyalgia), SPC-14 (Alzheimer's), SPU-16 (MS).","Exclusive licenses from Columbia University (SPC-15, SPC-14) and University of Maryland (SPU-16).","Company intends to use 505(b)(2) regulatory pathway for SPC-15 and SP-26 to shorten timelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207104,"accession_number":"0001013762-24-000518","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Silo Pharma raises $2.1M in registered direct offering of 763,638 shares at $2.75","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.1M from sale of 763,638 common shares at $2.75 each.","Concurrent private placement of warrants to buy 763,638 shares at $2.75, exercisable for 5 years.","H.C. Wainwright acted as exclusive placement agent; fees include 7.5% cash and 57,273 placement agent warrants.","Net proceeds to be used for working capital and general corporate purposes.","Offering closed on July 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207103,"accession_number":"0001213900-24-059821","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.","Agreement includes initial and annual fees from low to mid five figures, milestone payments, and royalties on net revenues.","Silo submitted a pre-IND briefing package to FDA and plans 505(b)(2) pathway to shorten clinical timelines and reduce costs.","Term runs per country/product until later of patent expiry, 20 years after first commercial sale, or end of market exclusivity.","CEO Eric Weisblum states the license is a critical step that could increase shareholder value subject to FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224448,"accession_number":"0001213900-24-056678","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Silo Pharma amends license milestones with University of Maryland, Baltimore","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fourth Amendment replaces Schedule C diligence milestones under the Master License Agreement.","New milestones include completing in vitro peptide binding by March 2025 and preclinical studies by September 2025.","IND filing for a Licensed Product due by February 2028; first commercial sale by February 2034.","All other terms, including royalty rate and payment obligations, remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224447,"accession_number":"0001213900-24-050405","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Silo Pharma raises $2M in registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 917,432 shares at $2.18/share and issued warrants for 917,432 shares at $2.06 exercise price.","Gross proceeds ~$2M; net proceeds for working capital and general corporate purposes.","H.C. Wainwright acted as exclusive placement agent; fees include 7.5% cash fee and 68,807 warrant shares.","Closing occurred June 6, 2024; warrants exercisable immediately for 5 years.","Officers and directors subject to 15-day lock-up; company restricted from variable-rate transactions for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224446,"accession_number":"0001213900-24-049658","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.","Pre-clinical data showed effective, consistent exposure in a non-GLP small animal study completed Feb 2024.","Silo expects to finalize an exclusive worldwide license with Columbia University in H1 2024.","Next steps: PIND and GLP studies both slated to commence in H2 2024 before IND submission.","Only two FDA-approved PTSD drugs exist; SPC-15 aims to increase stress resilience in high-risk populations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224445,"accession_number":"0001213900-24-030805","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma extends stock repurchase program to April 30, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved extension of $1.0M repurchase program until April 30, 2024.","As of March 31, 2024, repurchased 315,462 shares for $566,803.","Program has approximately $433,197 in remaining authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243754,"accession_number":"0001213900-24-008888","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma prioritizes 2024 pipeline targeting PTSD, chronic pain, neurology; plans Pre-IND for SPC-15 by Q2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lead program SPC-15 (intranasal PTSD prophylactic) Pre-IND submission planned by end of Q2 2024.","SP-26 is a non-opioid, time-release ketamine implant for fibromyalgia, potential first at-home ketamine treatment.","SPC-14 (Alzheimer's) positive animal results; more data expected in 2024; SPU-16 targets MS via homing peptide.","FDA 505(b)(2) pathway to be used for SPC-15, SP-26, and SPC-14 to expedite approval and reduce costs.","Pipeline includes four drugs across three therapeutic areas: mental health, chronic pain, and neurology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243752,"accession_number":"0001213900-24-002881","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K/A","filed_at":"2024-01-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma extends stock repurchase program of up to $1M through March 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved extension of stock repurchase program authorizing up to $1M in common stock purchases until March 31, 2024.","As of Dec 31, 2023, company repurchased 264,196 shares for total cost of $487,016 under the program.","Extension approved on January 9, 2024; original program was previously announced but not detailed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243753,"accession_number":"0001213900-24-002314","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma extends stock repurchase program up to $1M through March 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board extended stock repurchase program through March 31, 2024.","Authorization remains at up to $1 million of common stock.","Extension approved on January 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261158,"accession_number":"0001213900-23-097364","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K12B","filed_at":"2023-12-20T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Silo Pharma reincorporates from Delaware to Nevada, effective December 19, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reincorporation completed via Plan of Conversion approved by stockholders on Dec 4/11, 2023.","Each outstanding share of Delaware common stock converted one-for-one into Nevada common stock.","Options, warrants, and equity plans continue on same terms; no exchange of stock certificates required.","Ticker remains SILO on Nasdaq; business, management, and offices unchanged.","Stockholder rights now governed by Nevada law; differences detailed in Oct 23, 2023 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261162,"accession_number":"0001213900-23-094712","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Silo Pharma shareholders approve reincorporation from Delaware to Nevada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 3 approved with 1,589,197 For, 43,858 Against, 10,276 Abstain, 40,875 Broker Non-Vote.","Reincorporation from Delaware to Nevada was the sole item voted on at reconvened 2023 annual meeting.","Record date October 12, 2023; 3,109,497 shares outstanding; quorum was present.","Effective date of reincorporation not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261161,"accession_number":"0001213900-23-093122","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Silo Pharma reduces authorized shares to 100M, adjourns annual meeting for Nevada reincorporation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved decrease of authorized common stock from 500M to 100M; Certificate of Amendment filed Dec 4, 2023.","Annual meeting adjourned solely for Proposal 3 (reincorporation from Delaware to Nevada); other proposals approved.","Reconvened meeting set for Dec 11, 2023 at 11am ET in Sarasota, FL; record date Oct 12, 2023 unchanged.","Proxies already submitted will be voted on reincorporation; stockholders need not vote again."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261160,"accession_number":"0001213900-23-092761","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Silo Pharma shareholders approve 80% authorized share reduction and equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four directors elected: Weisblum, Linsley, Muñoz, Pavell (1.45M-1.45M for each).","Amended 2020 Omnibus Equity Incentive Plan approved (1.43M for, 97,553 against, 11,988 abstain).","Authorized common shares reduced from 500M to 100M (1.52M for, 2,648 against, 10,000 abstain).","Ratification of Salberg & Company as auditor approved (1.51M for, 189 against, 66,435 abstain).","Vote on reincorporation to Nevada adjourned to December 11, 2023; results to be filed later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261159,"accession_number":"0001213900-23-086959","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Silo Pharma amends U. Maryland license, sets new development milestones through 2033","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third Amendment to Master License Agreement replaces entire diligence milestone schedule (Schedule C).","Key new milestones: complete in vitro peptide binding study by March 30, 2024; preclinical safety/efficacy by Sept 30, 2024.","GMP production and animal testing deadline: Feb 12, 2026; IND filing by Feb 12, 2027; Phase 1 first dosing by Feb 12, 2028.","Phase 2 first dosing by Feb 12, 2029; NDA filing by Feb 12, 2032; first commercial sale by Feb 12, 2033.","Royalty and other payment obligations under original MLA remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278426,"accession_number":"0001213900-23-072602","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma files PCT patent for Alzheimer's treatment using prucalopride and ketamine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PCT patent application filed on August 25, 2023, for methods treating Alzheimer's disease.","Treatment combines prucalopride (5-HT4 agonist) with ketamine (NMDA antagonist).","Application seeks international patent protection; no granted status or trial data reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296589,"accession_number":"0001213900-23-052948","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma extends license agreement with University of Maryland through Sept 2023, with option to Dec 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Term of Commercial Evaluation and License Agreement extended to September 30, 2023.","Company may further extend to December 31, 2023 by paying $2,500 fee and providing notice by August 31, 2023.","Amendment executed June 28, 2023; fee creditable against future patent expenses if master license signed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317016,"accession_number":"0001213900-23-022970","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma files provisional patent for ketamine pain management (SP-26) targeting fibromyalgia.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Provisional patent titled 'Methods and Compositions for Pain Management' covers chronic pain including fibromyalgia.","Fibromyalgia affects approximately 2% of the U.S. population; initially targeted indication for company drug SP-26.","Company is working towards submitting an IND package to FDA under 505(b)(2) regulatory pathway for SP-26.","CEO Eric Weisblum states patent supports multi-pronged strategy to advance SP-26 into the clinic.","Silo Pharma holds over six issued and provisional patents in rare disease space."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317015,"accession_number":"0001213900-23-012084","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma files provisional patent for CNS-homing peptides to treat Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed provisional patent for CNS-homing peptides targeting Alzheimer's disease and dementia.","Peptides designed to reduce toxicity and improve therapeutic payload delivery to affected cells.","CEO Eric Weisblum cited unmet need for effective Alzheimer's treatments and targeted delivery approach.","Silo Pharma continues preclinical studies of novel therapeutics including psychedelic research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317014,"accession_number":"0001213900-23-007755","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma receives U.S. patent covering SPC-15 for stress-induced affective disorders","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["USPTO issued U.S. Patent 11,491,120 for SPC-15, a prophylactic using ketamine for anxiety and PTSD in females.","Patent protects method of treatment and prevention for stress-induced affective disorders including PTSD.","Silo holds option to license assets from Columbia University including potential treatments for Alzheimer's disease.","CEO Eric Weisblum highlighted scope of allowed claims and market potential for SPC-15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317013,"accession_number":"0001213900-23-006428","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma announces board-authorized stock repurchase program up to $1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $1M of common stock in open market or privately negotiated transactions.","Company had approximately 3,138,797 shares outstanding as of November 10, 2022.","Repurchases subject to available liquidity, cash flows, market conditions, and regulatory limits.","Program does not obligate the company to repurchase any specific amount and may be suspended or discontinued any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317012,"accession_number":"0001213900-23-003906","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Silo Pharma transmits three PCT patent applications to USPTO for psilocybin delivery","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Received notice of successful transmission to USPTO for three PCT patent applications.","Applications filed July 2021 relate to CNS-homing peptides delivering anti-inflammatory therapeutics with psilocybin.","National phase entries for these PCT applications are now at the USPTO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335262,"accession_number":"0001213900-22-076880","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silo Pharma provides pipeline update, cites $12M cash and zero debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash over $12M, no debt, listed on Nasdaq; pursuing 505(b)(2) pathway for several assets.","SP-26 (ketamine for fibromyalgia) preparing pre-IND submission; safety evaluation underway.","SPU-16 (MS) and SPU-21 (RA) under license from University of Maryland; SPU-21 inhibited arthritis in preclinical model.","SPC-14 (Alzheimer's) showed proof-of-concept in mouse model; SPC-15 (PTSD) under Columbia option.","Sponsored clinical study with UCSF on psilocybin's anti-inflammatory effects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335261,"accession_number":"0001213900-22-064735","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2022-10-18T23:59:59+00:00","items":["1.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Silo Pharma hires Eric Weisblum as CEO with $350K salary, extends Columbia research pact","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Weisblum appointed CEO; base salary $350K/yr, signing bonus $100K, annual bonus up to $350K.","Severance includes 24 months base salary, COBRA coverage, and prorated bonus on termination without cause or change in control.","Columbia University agreement extended; option to license SPC-14 (Alzheimer's) and SPC-15 (stress-induced anxiety).","CFO Daniel Ryweck salary increased to $60K/yr per amendment dated October 12, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352702,"accession_number":"0001213900-22-060406","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Silo Pharma closes $5.75M public offering at $5/share, uplists to Nasdaq; appoints new CFO and director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten offering of 1,150,000 shares (incl. full over-allotment) at $5.00/share, gross proceeds $5.75M, net ~$4.83M.","Common stock began trading on Nasdaq Capital Market under ticker SILO on September 27, 2022.","CFO Eric Weisblum resigned; remains CEO and President. Daniel Ryweck appointed CFO with $42,000 annual base salary.","Board appointed Dr. Jeff Pavell as director and chair of nominating and corporate governance committee.","Proceeds to fund product development, marketing, working capital, and potential acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352701,"accession_number":"0001213900-22-056294","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Silo Pharma implements 1-for-50 reverse stock split in preparation for Nasdaq uplisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at ratio of 1-for-50 effective 4:01 p.m. ET on September 14, 2022.","Common stock will trade on OTC Markets under temporary symbol 'SILOD' until Nasdaq listing.","Post-split shares outstanding approximately 1,987,906; fractional shares rounded up.","Stockholders approved reverse split range at special meeting on March 11, 2022.","Company has filed Nasdaq listing application and believes it meets all requirements except minimum share price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389385,"accession_number":"0001213900-22-011857","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2022-03-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Silo Pharma shareholders approve reverse stock split of 1-for-5 to 1-for-50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders granted Board discretion to effect a reverse split at a ratio between 1:5 and 1:50.","Reverse split must be completed by February 8, 2023.","Vote totals: 53,847,792 in favor, 11,915 against, 240 abstain.","Quorum of 53,859,947 shares represented at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389384,"accession_number":"0001213900-22-010964","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Silo Pharma corrects special meeting date to Friday March 11, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting of stockholders set for Friday, March 11, 2022 at 11:00 a.m. ET at 560 Sylvan Ave, Englewood Cliffs, NJ.","Proxy materials incorrectly listed meeting date as Thursday, March 11, 2022; correction confirms it is Friday.","No other changes to meeting agenda or business to be conducted; date correction only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389383,"accession_number":"0001213900-22-000462","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Silo Pharma sets director compensation: $25k retainer + options, $0.1460 strike, one-year vest","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-employee directors receive $25,000 cash retainer plus 177,233 option shares at $0.1460, one-year cliff vest.","Audit Committee Chair receives additional $12,500 cash fee.","Compensation Committee Chair receives additional $7,500 cash fee.","Option term is 5 years from grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407334,"accession_number":"0001213900-21-054869","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2021-10-27T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Silo Pharma partners with Columbia University on ketamine-based Alzheimer's therapeutic","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Sponsored research agreement with Columbia University to develop ketamine treatment for Alzheimer's disease.","Option to license novel inventions from Dr. Christine Ann Denny's lab targeting memory and cognitive aging.","No financial terms or specific milestones disclosed in the agreement.","Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on psychedelics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426318,"accession_number":"0001213900-21-050034","cik":1514183,"company_name":"Silo Pharma, Inc.","ticker":"SILO","form_type":"8-K","filed_at":"2021-09-27T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Silo Pharma sells 1M shares of DatChat for ~$6.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,000,000 shares of DatChat, Inc. for aggregate proceeds of approximately $6.6 million.","Transactions occurred between September 21 and September 23, 2021 via stock purchase agreements.","Shares sold to an institutional purchaser; agreements include lock-up release from EF Hutton.","The stake was previously disclosed in an August 18, 2021 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6794555.614628298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-27T23:59:59+00:00|426318"}